MARKET

LYRA

LYRA

Lyra Therapeutics, Inc.
OTCPK
0.495
-0.825
-62.50%
Closed 19:59 03/16 EDT
OPEN
1.290
PREV CLOSE
1.320
HIGH
1.327
LOW
0.485
VOLUME
1.40M
TURNOVER
0
52 WEEK HIGH
37.50
52 WEEK LOW
0.485
MARKET CAP
878.57K
P/E (TTM)
-0.0208
1D
5D
1M
3M
1Y
5Y
1D
Lyra Therapeutics Withdraws Appeal Of Nasdaq Delisting Determination; Trading In Co's Common Stock To Be Suspended At Open On March 17, 2026
Benzinga · 13h ago
Lyra Therapeutics Withdraws Nasdaq Appeal, Faces Imminent Delisting
TipRanks · 13h ago
LYRA THERAPEUTICS INC - TRADING IN LYRA THERAPEUTICS STOCK TO BE SUSPENDED AT OPEN ON MARCH 17, 2026 - SEC FILING
Reuters · 14h ago
Nasdaq to suspend Lyra Therapeutics shares on March 17 after delisting appeal withdrawal
Reuters · 14h ago
Weekly Report: what happened at LYRA last week (0309-0313)?
Weekly Report · 1d ago
Weekly Report: what happened at LYRA last week (0302-0306)?
Weekly Report · 03/09 10:34
Weekly Report: what happened at LYRA last week (0223-0227)?
Weekly Report · 03/02 10:33
Weekly Report: what happened at LYRA last week (0216-0220)?
Weekly Report · 02/23 10:33
More
About LYRA
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The Company is developing therapies for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210, the Company’s lead product, is a bioabsorbable nasal implant designed to be administered in a simple, in-office procedure and is intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS with a single administration. LYR-210, being evaluated in the ENLIGHTEN Phase III clinical program, is intended for patients with and without nasal polyps. The drug embedded within LYR-210 is mometasone furoate (MF).

Webull offers Lyra Therapeutics Inc stock information, including OTCPK: LYRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LYRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LYRA stock methods without spending real money on the virtual paper trading platform.